Gilead Sciences Inc
GILD107.250USD
-5.140-4.57%
收盘 04/04, 16:00（美东）报价延迟15分钟
133.63B总市值
278.40市盈率 TTM
关于 Gilead Sciences Inc 公司
吉利德科学公司是一家生物制药公司。该公司致力于开发预防和治疗危及生命的疾病的药物，包括人类免疫缺陷病毒 (HIV)、病毒性肝炎、2019 年冠状病毒病 (COVID-19) 和癌症。该公司专注于未满足医疗需求领域的药物发现、开发和商业化。其上市产品组合包括 AmBisome、Atripla、Biktarvy、Cayston、Complera、Descovy、Descovy for PrEP、Emtriva、Epclusa、Eviplera、Genvoya、Harvoni、Hepcludex、Hepsera、Jyseleca、Letairis、Odefsey、Sovaldi、Stribild、Sunlenca、Tecartus、Trodelvy、Truvada、Truvada for PrEP、Tybost、Veklury、Vemlidy、Viread、Vosevi、Yescarta 和 Zydelig。其候选产品包括 Bulevirtide、Lenacapavir、Axicabtagene ciloleucel、Domvanalimab 和 zimberelimab 以及 seladelpar。Seladelpar 用于治疗原发性胆汁性胆管炎 (PBC)，包括瘙痒症。该公司在 35 多个国家开展业务。
公司简介
公司代码GILD
公司名称Gilead Sciences Inc
上市日期Jan 22, 1992
成立日期1987
CEOMr. Daniel P O'Day
员工数量17600
证券类型Ordinary Share
年结日Jan 22
公司地址333 Lakeside Dr
城市FOSTER CITY
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94404-1147
电话16505743000
网址https://www.gilead.com/
公司代码GILD
上市日期Jan 22, 1992
成立日期1987
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
96.93K
+4.50%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
24.54K
--
Ms. Deborah H. (Deb) Telman
Ms. Deborah H. (Deb) Telman
Executive Vice President - Corporate Affairs, General Counsel
Executive Vice President - Corporate Affairs, General Counsel
19.55K
+12.77%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
10.23K
--
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Dr. Jeffrey A. (Jeff) Bluestone, Ph.D.
Dr. Jeffrey A. (Jeff) Bluestone, Ph.D.
Independent Director
Independent Director
--
--
Dr. Dietmar P. Berger, M.D., Ph.D.
Dr. Dietmar P. Berger, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Ted W. Love, M.D.
Dr. Ted W. Love, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
96.93K
+4.50%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
24.54K
--
Ms. Deborah H. (Deb) Telman
Ms. Deborah H. (Deb) Telman
Executive Vice President - Corporate Affairs, General Counsel
Executive Vice President - Corporate Affairs, General Counsel
19.55K
+12.77%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
10.23K
--
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
收入明细
单位: USD更新时间: 5 小时前
单位: USD更新时间: 5 小时前
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
业务USD
名称
营收
占比
Biktarvy
13.42B
46.69%
Descovy
2.11B
7.35%
Genvoya
1.76B
6.13%
Sofosbuvir/Velpatasvir
1.59B
5.55%
Yescarta
1.57B
5.46%
Other
8.29B
28.83%
地区USD
名称
营收
占比
United States
19.51B
67.84%
Europe
4.35B
15.12%
Other Locations
2.91B
10.11%
业务
地区
业务USD
名称
营收
占比
Biktarvy
13.42B
46.69%
Descovy
2.11B
7.35%
Genvoya
1.76B
6.13%
Sofosbuvir/Velpatasvir
1.59B
5.55%
Yescarta
1.57B
5.46%
Other
8.29B
28.83%
股东统计
更新时间: 2月21日 周五
更新时间: 2月21日 周五
持股股东
股东类型
持股股东
股东统计
占比
The Vanguard Group, Inc.
9.22%
BlackRock Institutional Trust Company, N.A.
5.97%
Capital World Investors
5.75%
State Street Global Advisors (US)
4.84%
Capital Research Global Investors
4.65%
Other
69.56%
持股股东
股东统计
占比
The Vanguard Group, Inc.
9.22%
BlackRock Institutional Trust Company, N.A.
5.97%
Capital World Investors
5.75%
State Street Global Advisors (US)
4.84%
Capital Research Global Investors
4.65%
Other
69.56%
股东类型
股东统计
占比
Investment Advisor
42.57%
Investment Advisor/Hedge Fund
35.44%
Research Firm
3.19%
Pension Fund
3.00%
Sovereign Wealth Fund
1.73%
Bank and Trust
1.70%
Hedge Fund
1.59%
Insurance Company
0.15%
Foundation
0.13%
Other
10.50%
机构持股
更新时间: 1月19日 周日
更新时间: 1月19日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q1
3239
1.12B
90.06%
+5.93M
2024Q4
3313
1.12B
90.13%
+4.63M
2024Q3
3207
1.10B
88.48%
-11.56M
2024Q2
3188
1.10B
88.24%
-14.37M
2024Q1
3196
1.10B
88.13%
-22.04M
2023Q4
3252
1.11B
88.75%
-8.79M
2023Q3
3190
1.10B
88.14%
-23.58M
2023Q2
3196
1.10B
88.02%
-11.22M
2023Q1
3195
1.09B
87.26%
-11.17M
2022Q4
3203
1.08B
86.64%
+1.09M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
114.97M
9.22%
+203.25K
+0.18%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
74.47M
5.97%
-1.75M
-2.30%
Dec 31, 2024
Capital World Investors
71.71M
5.75%
-4.84M
-6.33%
Dec 31, 2024
State Street Global Advisors (US)
60.38M
4.84%
+210.06K
+0.35%
Dec 31, 2024
Capital Research Global Investors
57.95M
4.65%
-3.85M
-6.24%
Dec 31, 2024
Wellington Management Company, LLP
35.66M
2.86%
+1.06M
+3.06%
Dec 31, 2024
Fidelity Management & Research Company LLC
34.64M
2.78%
+6.42M
+22.73%
Dec 31, 2024
Dodge & Cox
32.95M
2.64%
-98.02K
-0.30%
Dec 31, 2024
Geode Capital Management, L.L.C.
28.29M
2.27%
+749.05K
+2.72%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
25.78M
2.07%
+346.10K
+1.36%
Feb 28, 2025
查看更多
持股ETF
更新时间: 23 小时前
更新时间: 23 小时前
机构名称
占比
VanEck Biotech ETF
12%
Invesco Nasdaq Biotechnology ETF
10.22%
ProShares Ultra Nasdaq Biotechnology
7.84%
iShares Biotechnology ETF
7.01%
Invesco Biotechnology & Genome ETF
6.3%
First Trust NASDAQ Pharmaceuticals ETF
6.11%
VanEck Morningstar Wide Moat Value ETF
5.8%
Global X US Cash Flow Kings 100 ETF
5.67%
Simplify Health Care ETF
4.99%
USCF Dividend Income Fund
4.95%
查看更多
VanEck Biotech ETF
占比12%
Invesco Nasdaq Biotechnology ETF
占比10.22%
ProShares Ultra Nasdaq Biotechnology
占比7.84%
iShares Biotechnology ETF
占比7.01%
Invesco Biotechnology & Genome ETF
占比6.3%
First Trust NASDAQ Pharmaceuticals ETF
占比6.11%
VanEck Morningstar Wide Moat Value ETF
占比5.8%
Global X US Cash Flow Kings 100 ETF
占比5.67%
Simplify Health Care ETF
占比4.99%
USCF Dividend Income Fund
占比4.95%
分红派息
近5年累计派现
18.49B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Feb 11, 2025
GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Mar 28, 2025 going ex on Mar 14, 2025
Mar 14, 2025
Mar 28, 2025
Mar 14, 2025
Nov 12, 2024
GILD.NB Final Cash Dividend of gross USD 0.77 paid on Dec 30, 2024 going ex on Dec 13, 2024
Dec 13, 2024
Dec 30, 2024
Dec 13, 2024
Aug 13, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Sep 27, 2024 going ex on Sep 13, 2024
Sep 13, 2024
Sep 27, 2024
Sep 13, 2024
Apr 26, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Jun 27, 2024 going ex on Jun 14, 2024
Jun 14, 2024
Jun 27, 2024
Jun 14, 2024
Feb 06, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Mar 28, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Mar 28, 2024
Mar 14, 2024
Nov 08, 2023
GILD.NB Final Cash Dividend of gross USD 0.75 paid on Dec 28, 2023 going ex on Dec 14, 2023
Dec 15, 2023
Dec 28, 2023
Dec 14, 2023
Aug 07, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Sep 28, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Sep 28, 2023
Sep 14, 2023
Apr 28, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Jun 29, 2023 going ex on Jun 14, 2023
Jun 15, 2023
Jun 29, 2023
Jun 14, 2023
Feb 02, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Mar 30, 2023 going ex on Mar 14, 2023
Mar 15, 2023
Mar 30, 2023
Mar 14, 2023
Oct 27, 2022
GILD.NB Final Cash Dividend of gross USD 0.73 paid on Dec 29, 2022 going ex on Dec 14, 2022
Dec 15, 2022
Dec 29, 2022
Dec 14, 2022
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据